Sai Parenteral's Ltd. (SAIPARENT) — Tipsheet https://tipsheet.markets/company/saiparent/ Every Tipsheet Editorial note covering Sai Parenteral's Ltd. (SAIPARENT), newest first. Grounded in BSE/NSE primary-source filings. en-in Tue, 28 Jul 2026 14:38:35 GMT Sai Parenterals locks in ₹1,300-cr Australian OTC deal, 3.4x annual revenue https://tipsheet.markets/saiparent-sai-parenterals-locks-in-1-300-cr-australian-otc-deal-3-4x-annual-revenue-117964/ https://tipsheet.markets/saiparent-sai-parenterals-locks-in-1-300-cr-australian-otc-deal-3-4x-annual-revenue-117964/ Wed, 01 Jul 2026 16:38:05 GMT The 7.5-year exclusive supply contract validates the Noumed acquisition and provides transformational scale for the ₹2,586-cr market-cap company. The 7.5-year exclusive supply contract validates the Noumed acquisition and provides transformational scale for the ₹2,586-cr market-cap company.

What’s new

  • Noumed signed an exclusive 7.5-year OTC supply deal with Australia's largest pharmacy network.
  • Contract value of ₹1,300 cr equals 3.4x Sai Parenterals' FY26 consolidated revenue of ₹381 cr.
  • Deal effective July 1, with an option to extend by three more years.

Why it matters

For a small-cap with ₹381 cr revenue, a single contract worth 3.4x that transforms revenue visibility. It validates the Noumed acquisition and positions Sai to service regulated markets at scale. Earnings upgrades are all but certain.

What we’re watching

  • Execution ramp-up: Noumed must deliver OTC volumes consistently over seven years.
  • Debt trajectory: Sai had projected peak net debt of ₹319 cr in FY27; cash flows from this deal should accelerate deleveraging.
  • Whether this opens doors for additional contracts with the same pharmacy chain or other Australian retailers.

The full read

Sai Parenterals' Australian subsidiary Noumed has signed an exclusive 7.5-year contract with the country's largest pharmacy network to supply OTC medicines. The deal is worth AUD 202 million (roughly ₹1,300 crore), or 3.4 times the Hyderabad drugmaker's entire FY26 consolidated revenue of ₹381 crore. The contract, effective July 1, also includes a three-year extension option. A deal of this scale for a small-cap pharma is rare. It validates the manufacturing capabilities that came with last November's Noumed acquisition and gives the company multi-year revenue visibility that few peers enjoy. The company had earlier projected FY27 revenue of ₹750 crore and peak net debt of ₹319 crore. This contract alone could rewrite those numbers. Execution risk remains (Noumed must deliver consistently over seven years), but the structural shift is unmistakable.

Primary source: BSE · NSE

]]> Order Wins Tipsheet Editorial Sai Parenterals sees ₹750 cr revenue this year, will carry peak debt of ₹319 cr https://tipsheet.markets/saiparent-sai-parenterals-sees-750-cr-revenue-this-year-will-carry-peak-debt-of-319-cr-100234/ https://tipsheet.markets/saiparent-sai-parenterals-sees-750-cr-revenue-this-year-will-carry-peak-debt-of-319-cr-100234/ Wed, 27 May 2026 16:52:44 GMT Management guided for ₹750 crore in revenue and a 17% EBITDA margin in FY27, a year it calls the peak for debt as it spends ₹440 cr on capex. Management guided for ₹750 crore in revenue and a 17% EBITDA margin in FY27, a year it calls the peak for debt as it spends ₹440 cr on capex.

What’s new

  • Sai Parenterals guided for ₹750 cr revenue and a 17% EBITDA margin in FY27.
  • Company is executing a ₹440 cr capex plan, with its Australian facility due by March 2027.
  • FY27 is the peak debt year at ₹319 cr net debt; decline is expected from FY28.

Why it matters

The call lays out a clear financial bridge: a big spending year to build assets, followed by a pivot to monetisation. The ₹319 crore debt peak is the cost, and the 2.4 percentage point margin lift from the Nu-Med integration is the promised payoff. Whether the assets deliver as planned is now the core question.

What we’re watching

  • Execution on the ₹440 cr capex and the March 2027 Adelaide commissioning date.
  • Whether Nu-Med backward integration delivers the guided 2.4 pp margin lift starting in Q4.
  • The actual trajectory of debt reduction from FY28.

The full read

Sai Parenterals is guiding for ₹750 crore in revenue this year. The margin target is 17%. Those numbers sit on top of a ₹440 crore capex push that will peak the company's balance sheet. Management said FY27 will be the high-water mark for debt, with net debt hitting ₹319 crore before dropping from FY28. The bet is specific: a new facility in Adelaide, due by March 2027, and backward integration at the Nu-Med subsidiary starting in Q4. That integration alone should add 2.4 percentage points to EBITDA margin. The call frames this as the end of the investment cycle and the start of asset monetisation. Not yet.

Primary source: BSE · NSE

]]> Earnings Tipsheet Editorial